Accès ouvert déclaré
2024
article
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort
Antonella d’Arminio Monforte, Alessandro Tavelli, Antonio Di Biagio, Loredana Sarmati, Giulia Marchetti, Francesca Bai, Antonella Cingolani, Eugenio Quiros Roldan, Cristina Mussini, Miriam Lichtner, Alessandra Vergori, Stefania Piconi, Giancarlo Orofino, Francesco Maria Fusco, Alessandra Bandera, Silvia Nozza, Antonella Castagna, Andrea Antinori, Spinello Antinori, Roberto Cauda, Giovanni Di Perri, Enrico Girardi, R Iardino, Adriano Lazzarin, C Mussini, Eugenia Quirós-Roldán, Barbara Suligoi, F von Schloesser, Pierluigi Viale, Francesca Ceccherini‐Silberstein, Alessandro Cozzi‐Lepri, Andrea Gori, Sergio Lo Caputo, G Marchetti, Franco Maggiolo, Massimo Puoti, Carlo Federico Perno, Carlo Torti, Stefano Bonora, Andrea Calcagno, Diana Canetti, A Cervo, Paola Cinque, Roberta Gagliardini, Andrea Giacomelli, Nicola Gianotti, G Guaraldi, Simone Lanini, Giuseppe Lapadula, Alessia Lai, Giordano Madeddu, Vincenzo Malagnino, Annalisa Mondi, Valentina Mazzotta, Carmela Pinnetti, Roberto Rossotti, Stefano Rusconi, Maria Mercedes Santoro, Annalisa Saracino, Vincenzo Spagnuolo, Nicola Squillace, Valentina Svicher, Lucia Taramasso, S De Benedittis, Iuri Fanti, M Giotta, A Rodano’, Albert Bové, Massimo Cernuschi, L Cosmaro, Massimiliano Errico, A Perziano, Valeria Calvino, Matteo Augello, Silvia Carrara, Silvia Graziano, Gennaro Prota, S Truffa, Donatella Vincenti, Roberta Rovito, Andrea Giacometti, Andrea Costantini, V Barocci, Carmen Rita Santoro, Eugenio Milano, Laura Comi, Claudia Suardi, Lorenzo Badia, Silvia Cretella, E M Erne, A Pieri, Emanuele Focà, C Minardi, Barbara Menzaghi, C Abeli, Luchino Chessa, Francesco Pes, Paolo Maggi, Loredana Alessio, Bruno Cacopardo, Benedetto Maurizio Celesia, Jacopo Vecchiet, Katia Falasca, Angelo Pan, Sarah Dal Zoppo, Daniela Segala, Massimo Antonio Di Pietro, Cecilia Costa, Sergio Ferrara, Matteo Bassetti, Emanuele Pontali, Sophie Blanchi, Nicoletta Bobbio, Giovanni Mazzarello, Laura Fondaco, Chiara Molteni, G Canavesi, Giuseppe Nunnari, Giovanni Francesco Pellicanò, Giuliano Rizzardini, Valeria Bono, Maria Vittoria Cossu, Riccardo Lolatto, M C Moioli, Laura Pezzati, S Diotallevi, Camilla Tincati, Cinzia Puzzolante, Paolo Bonfanti, Vincenzo Sangiovanni, Ivan Gentile, Vincenzo Esposito, Nicola Coppola, Giovanni Di Filippo, Viviana Rizzo, N Sangiovanni, Salvatore Martini, Anna Maria Cattelan, D Leoni, Antonio Cascio, Claudia Colomba, Daniela Francisci, Elisabetta Schiaroli, Giustino Parruti, Federica Sozio, Pierluigi Blanc, Sara Irene Bonelli, C Lazzaretti, R Corsini, Claudio Maria Mastroianni, Alessandra Latini, Silvia Lamonica, M Capozzi, Marco Rivano Capparuccia, Giancarlo Iaiani, C Stingone, L Gianserra, Jessica Paulicelli, Maria Maddalena Plazzi, G d’Ettore, Marisa Fusto, I Coledan, Andrea De Vito, Massimiliano Fabbiani, Francesca Montagnani, Anaïs Franco‐Romero, Rosario Vecchio, B M Pasticci, C Di Giuli, Guido Calleri, Giacomo Accardo, Carlo Tascini, AP Londero, Vinicio Manfrin, Giuliana Battagin, Giulio Starnini, Damiano Farinacci
11Citations signalées — pas une note de qualité
19Institutions déclarées
1Pays d’affiliation déclarés
Résumé fourni par la source
OBJECTIVES: To assess the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) among people poorly represented in clinical trials and potentially at higher risk of suboptimal response to ART. METHODS: Observational cohort study on persons with HIV (PWH) enrolled in ICONA who started BIC/FTC/TAF as initial therapy or as switching regimen while virologically suppressed. Primary endpoint was time to treatment failure (TF): new AIDS/death or virological failure (VF) or discontinuation for toxicity/failure. Secondary endpoints were time to treatment discontinuation for toxicity (TDT) and to VF. Groups of interest were those aged >50 years, female sex, and advanced HIV disease at first ART start. Probability of the events overall and according to groups and adjusted HR for every endpoint were calculated by Kaplan-Meier curves and Cox regression models. RESULTS: Nine hundred and thirty-three ART-naive and 1655 ART-experienced PWH initiated BIC/FTC/TAF. Over a median follow-up of 69.8 weeks, 89 (9.6%) PWH at their first regimen experienced TF. PWH aged >50 years had 1.83-fold (95% CI: 1.19-2.83) higher risk of TF; PWH with advanced HIV disease had 2.21-fold (95% CI: 1.53-3.82) higher risk; there were no differences in TF according to sex.Over a median follow-up of 146.3 weeks, 109 (6.6%) out of 1655 switching PWH experienced TF; no differences were found in the risk of TF, TDT and VF according to groups of interest. CONCLUSIONS: Overall, BIC/FTC/TAF is well tolerated and virologically effective in the real-world scenario for ART-naive and -experienced PWH. Older ART-naive PWH and those with advanced HIV disease may respond less well as the burden of diseases might compromise treatment efficacy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort
- Date Crossref
- 06/04/2024
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.
Institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Sujets associés
HIV/AIDS drug development and treatmentHIV-related health complications and treatmentsHIV/AIDS Research and Interventions